Blueprint Medicines to regain global rights to Gavreto from Roche
Blueprint Medicines Corporation announced it will regain global commercialization and development rights to Gavreto (pralsetinib), excluding Greater China, following a decision by Roche to discontinue the collaboration agreement between the companies for Gavreto for strategic reasons
Under the terms of the agreement, the termination will be effective 12 months from the notification date of February 22, 2023. During the transition period, Blueprint Medicines and Roche are mutually committed to ensuring a smooth transition process with no anticipated interruptions or changes to patient access. In addition, the company will explore options to advance and simplify the continued global commercialization and development of Gavreto.
Since the initiation of the collaboration with Roche in July 2020, Blueprint Medicines has benefited from approximately $1 billion between upfront and milestone payments and from cost-sharing the commercialization and development of Gavreto.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins